Tetraphase Pharmaceuticals Competitors and Similar CompaniesClear all

Tetraphase Pharmaceuticals's competitors and similar companies include H3 Biomedicine, Cipla, Mankind Pharma and Alembic Pharmaceuticals.

	Tetraphase Pharmaceuticals Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.	H3 Biomedicine H3 Biomedicine is a biopharmaceutical company that specializes in cancer genomics.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.	Mankind Pharma Mankind Pharma is a pharmaceutical company developing, commercializing, and delivering medicines.	Alembic Pharmaceuticals Alembic Pharmaceuticals is a company that develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and intermediates
Founding Date	Founding Date 2006	Founding Date 2011	Founding Date 1935	Founding Date 1995	Founding Date 1907
Type	Type Subsidiary	Type Subsidiary	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Watertown, US HQ Waltham, US	Locations Cambridge, US HQ	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more	Locations New Delhi, IN HQ	Locations Vadodara, IN HQ Baska, IN Mumbai, IN Namthang, IN Vadodara, IN Vadodara, IN
Employees	Employees 14	Employees 378% decrease	Employees 27,764	Employees 15,5112% increase	Employees 14,858
Financial
Revenue (est.)	Revenue (est.) $7.4m (FY, 2019)	Revenue (est.) N/A	Revenue (est.) ₹254.5b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) ₹61.1b (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ₹88.2b (FY, 2024)	Cost of goods N/A	Cost of goods ₹19.3b (FY, 2024)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ₹169.5b (FY, 2024)	Gross profit N/A	Gross profit ₹43b (FY, 2024)
Net income	Net income ($70.1m) (FY, 2019)	Net income N/A	Net income ₹41.6b (FY, 2024)	Net income N/A	Net income ₹6.2b (FY, 2024)
Operating ⚠
Products	Products N/A	Products N/A	Products 1.5 k (FY, 2024)	Products N/A	Products 145 (FY, 2024)
Funding
Total funding raised	Total funding raised $ 94.8m	Total funding raised $ 200m	Total funding raised N/A	Total funding raised $ 239m	Total funding raised N/A